CALML6 Controls TAK1 Ubiquitination and Confers Protection against Acute Inflammation.
Chunjie ShengZiyang WangChen YaoHui-Ming ChenGuangyan KanDan WangHongyuan ChenShuai ChenPublished in: Journal of immunology (Baltimore, Md. : 1950) (2020)
Proper regulation of innate immune response is important for individual health. The NF-κB signaling pathway plays crucial roles in innate immunity and inflammation, and its aberrant activation is implicated in diverse diseases and disorders. In this study, we report that calmodulin-like 6 (CALML6), a member of the EF-hand protein family, is a negative regulator of the NF-κB signaling pathway. CALML6 attenuated TNF-stimulated phosphorylation of proteins downstream of TGF-β-activated kinase 1 (TAK1) and inhibited TAK1-induced NF-κB activation. Further studies showed that CALML6 interacted with TAK1 and recruited the deubiquitylating enzyme cylindromatosis to repress the K63-linked polyubiquitination of TAK1. CALML6 transgenic mice had higher tolerances to lethal LPS treatment in vivo. These findings suggest that CALML6 is a negative regulator of the NF-κB signaling pathway, which is important for maintaining the balance of the innate immune response.
Keyphrases
- signaling pathway
- immune response
- pi k akt
- oxidative stress
- induced apoptosis
- epithelial mesenchymal transition
- protein kinase
- lps induced
- healthcare
- dendritic cells
- toll like receptor
- rheumatoid arthritis
- transcription factor
- public health
- drug induced
- inflammatory response
- nuclear factor
- transforming growth factor
- liver failure
- intensive care unit
- climate change
- diabetic rats
- mental health
- hepatitis b virus
- binding protein
- health promotion
- small molecule
- endothelial cells